Menu
Back to Journals » Drug Design, Development and Therapy » Volume 15
Original Research
Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 4,814 | Dovepress* | 4,226+ | 877 | 5,103 | |
| PubMed Central* | 588 | 188 | 776 | ||
| Totals | 4,814 | 1,065 | 5,879 | ||
| *Since 7 January 2021 | |||||
View citations on PubMed Central and Google Scholar